Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotera Health CoSHC -0.84%74 Earnings Yield (Joel Greenblatt) % is 5.87% as of Mar. 2026, which is 56% above its 10-year median of 3.77. GuruFocus rates SHC with a GF Scoreâ„¢ of 74/100 and a GF Valueâ„¢ of $16.38 (Fairly Valued). The stock has 3 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Sotera Health Co ranks better than 80.28% on this metric.
Sotera Health Co's Enterprise Value for the quarter that ended in Mar. 2026 was $6,045 Mil.
Sotera Health Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $355 Mil. Sotera Health Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 5.87%.
The historical rank and industry rank for Sotera Health Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
SHC'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4.06 Med: 3.77 Max: 7.68
Current: 5.17
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Sotera Health Co was 7.68%. The lowest was -4.06%. And the median was 3.77%.
SHC's Earnings Yield (Joel Greenblatt) % is ranked better than 80.28% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.43
vs SHC: 5.17
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Sotera Health Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Sotera Health Co (NAS:SHC) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Sotera Health Co Earnings Yield (Joel Greenblatt) % Related Terms
Sotera Health Co Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotera Health Co Earnings Yield (Joel Greenblatt) % Chart
For the Diagnostics & Research subindustry, Sotera Health Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co Earnings Yield (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's Earnings Yield (Joel Greenblatt) % falls into.
Sotera Health Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Sotera Health Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Sotera Health Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $355 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 5.87% mean?
Sotera Health Co (SHC) has a Earnings Yield (Joel Greenblatt) % of 5.87% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Sotera Health Co and its competitors. This is 56% above median its historical median of 3.77. According to the industry distribution chart, Sotera Health Co ranks #42 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 19.7%.
Is Sotera Health Co's Earnings Yield (Joel Greenblatt) % too high?
Sotera Health Co's current Earnings Yield (Joel Greenblatt) % of 5.87% is 56% above median its 10-year median of 3.77. Based on the distribution chart, Sotera Health Co ranks #42 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Sotera Health Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's Earnings Yield (Joel Greenblatt) % compare to RDNT and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #42 out of 213 companies for Earnings Yield (Joel Greenblatt) %. This places Sotera Health Co in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good Earnings Yield (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Sotera Health Co and its competitors. Sotera Health Co's current Earnings Yield (Joel Greenblatt) % is 5.87%, which is 56% above median its own 10-year median of 3.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Fairly Valued. The stock's GF Value™ is $16.38, compared to a current price of $17.21 — trading 5% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 5.87%, which is 56% above median its 10-year median of 3.77. Sotera Health Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Sotera Health Co (SHC), the current Earnings Yield (Joel Greenblatt) % is 5.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $17.21 is trading 5% above its estimated GF Value™ of $16.38.
GuruFocus considers Sotera Health Co to be Fairly Valued.
Key valuation signals for SHC:
Earnings Yield (Joel Greenblatt) %: 5.87% (56% above median its 10-year median of 3.77)
GF Value™: $16.38 vs. price of $17.21 (5% above fair value)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score
Get the complete analysis for SHC
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
